论文部分内容阅读
在心力衰竭诊断的生化指标方面,BNP的应用范围扩大;此外,新指标(NT-proBNP,STZ)受到关注。心脏超声方面,组织多普勒法显示对心力衰竭病情评价有效。CT、MRI、PET等心脏影像技术的发展,使各种心功能评价方法成为可能。CIBISⅢ等大型临床试验结果为心力衰竭的药物疗法提供了新的证据。在药物疗法方面,β受体阻断剂疗法确立以来没有大的进步。心力衰竭的非药物疗法(HOT、CPAP、CRT、ICD、LVAD)不断进步,慢性期效果也得到证实。心力衰竭发病的分子水平机制部分得以阐明。组织工程学、发生学、纳米技术的新治疗方法的开发正在兴起。
In the biochemical indicators of heart failure diagnosis, the application of BNP expanded; in addition, new indicators (NT-proBNP, STZ) of concern. In terms of echocardiography, tissue Doppler imaging is effective in evaluating heart failure. The development of cardiac imaging technology such as CT, MRI and PET has made it possible to evaluate a variety of cardiac function. CIBIS Ⅲ and other large clinical trial results provide new evidence of drug therapy for heart failure. There has been no major improvement in pharmacotherapy since the establishment of beta-blocker therapy. Non-drug treatment of heart failure (HOT, CPAP, CRT, ICD, LVAD) continues to progress, and chronic phase effects have also been demonstrated. The molecular mechanism of the pathogenesis of heart failure is elucidated. The development of new treatments for tissue engineering, genetics and nanotechnology is on the rise.